Regulatory incentives, orphan drug policies, and precision medicine are driving pharma companies like Roche, Novartis, copyright and Takeda to accelerate rare disease portfolio expansion. https://finance.yahoo.com/news/rare-disease-therapeutics-market-surpass-150000687.html